Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at the American Society of Clinical Oncology (ASCO ...
Ladies and gentlemen, thank you for standing by. Welcome to the Cardiff Oncology ASCO Data Presentation Conference Call. [Operator Instructions] Please be advised that today's conference is being ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
ABSTRACT: The study describes the modeling of flood events of an ungauged river by using recorded data from a neighboring watershed. The Fenton and Mount Hope Rivers are two tributaries of the Thames ...
Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...
Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.
Florida-Based AP Governance Firm Selected as RFP-Stage Contender, Reinforcing Its Authority in Enterprise SAP Vendor Master Data Compliance and Modernization PORT ST. LUCIE, Fla., May 10, 2026 / PRZen ...
Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...
Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.
AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results